Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.35 |
| ▸ | CCR2 | P41597 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11569817 | 1.00 | SLC6A2 (0.35) | SLC6A2SLC6A4SLC6A3CCR2 | |
| SCHEMBL1073590 | 1.00 | SLC6A2 (0.35) | SLC6A2SLC6A4SLC6A3CCR2 | |
| SCHEMBL11287172 | 0.95 | GAA (0.30) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL11576962 | 0.89 | GAA (0.30) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL11577452 | 0.89 | GAA (0.30) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL11784129 | 0.86 | SLC6A2 (0.44) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL11791349 | 0.86 | SLC6A2 (0.44) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL8861264 | 0.81 | CYP1A2 (0.39) | — | |
| SCHEMBL21462929 | 0.81 | CYP1A2 (0.39) | — | |
| SCHEMBL22996132 | 0.80 | GAA (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0787721-B1 | 4a-ARYLDECAHYDROISOQUINOLINE COMPOUNDS AND MEDICINAL USES THEREOF | TORAY INDUSTRIES (JP) | 1999-04-28 | — | — | EP | claimed |
| US-5776945-A | CARDIOVASCULAR, CEREBRAL CYTOPROTECTIVE | TORAY INDUSTRIES, INC. (JP) | 1998-07-07 | — | — | US | claimed |
| EP-0787721-A1 | 4a-ARYLDECAHYDROISOQUINOLINE COMPOUNDS AND MEDICINAL USES THEREOF | TORAY INDUSTRIES, INC. (JP) | 1997-08-06 | — | — | EP | claimed |
| US-4435572-A | FROM 3-METHOXYBENZALDEHYDE | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1984-03-06 | — | — | US | claimed |
| US-4189583-A | FROM 1-METHYL-2-OXO-3-METHYLENE-4-(3'-METHOXYPHENYL)-4 -(CARBOXYMETHYLENE)PIPERIDINE BY CYCLIZATION | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH, EDUCATION AND WELFARE (US) | 1980-02-19 | — | — | US | claimed |
| JP-56071076-A | — | — | None | — | — | JP | disclosed |
| JP-8208618-A | — | — | None | — | — | JP | disclosed |
| US-20120178781-A1 | KAPPA OPIOID RECEPTOR LIGANDS | RESEARCH TRIANGLE INSTITUTE (US) | 2012-07-12 | — | — | US | disclosed |
| EP-1848275-B1 | KAPPA OPIOID RECEPTOR LIGANDS | RES TRIANGLE INST (US) | 2012-05-02 | — | — | EP | disclosed |
| US-8048895-B2 | Kappa opioid receptor ligands | RESEARCH TRIANGLE INSTITUTE (US) | 2011-11-01 | — | — | US | disclosed |
| US-7872023-B2 | administering 6-Hydroxy-1,2,3,4-tetrahydro-naphthalene-2(-)-carboxylic acid{1-[4-(3-hydroxyphenyl)-(3R)-(4R)-trans-dimethyl-piperidinylmethyl]-(2S)-methylpropyl}-amide, for the treatment of drug abuse and dependence | RESEARCH TRIANGLE INSTITUTE (US) | 2011-01-18 | — | — | US | disclosed |
| US-20090264462-A1 | KAPPA OPIOID RECEPTOR LIGANDS | RESEARCH TRIANGLE INSTITUTE (US) | 2009-10-22 | — | — | US | disclosed |
| US-4189583-A | FROM 1-METHYL-2-OXO-3-METHYLENE-4-(3'-METHOXYPHENYL)-4 -(CARBOXYMETHYLENE)PIPERIDINE BY CYCLIZATION | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH, EDUCATION AND WELFARE (US) | 1980-02-19 | — | — | US | disclosed |
| US-4189583-A | FROM 1-METHYL-2-OXO-3-METHYLENE-4-(3'-METHOXYPHENYL)-4 -(CARBOXYMETHYLENE)PIPERIDINE BY CYCLIZATION | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH, EDUCATION AND WELFARE (US) | 1980-02-19 | — | — | US | disclosed |
| US-4189583-A | FROM 1-METHYL-2-OXO-3-METHYLENE-4-(3'-METHOXYPHENYL)-4 -(CARBOXYMETHYLENE)PIPERIDINE BY CYCLIZATION | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH, EDUCATION AND WELFARE (US) | 1980-02-19 | — | — | US | disclosed |
| EP-0002937-A1 | Novel pyrindines and their preparation, formulations and use | ELI LILLY AND COMPANY (US) | 1979-07-11 | — | — | EP | disclosed |
| US-4150135-A | ANALGESICS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1979-04-17 | — | — | US | disclosed |
| US-4150135-A | ANALGESICS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1979-04-17 | — | — | US | disclosed |
| US-4141893-A | Decahydrocyclopent[c]azepines | ELI LILLY AND COMPANY (US) | 1979-02-27 | — | — | US | disclosed |
| US-4077954-A | ANALGESICS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1978-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178781-A1 | KAPPA OPIOID RECEPTOR LIGANDS | OPRK1, OPRD1, OPRM1 | SLC6A2 522/4885SLC6A4 667/4885SLC6A3 191/4885 |
| US-20090264462-A1 | KAPPA OPIOID RECEPTOR LIGANDS | OPRK1, OPRD1, OPRM1 | SLC6A2 522/4885SLC6A4 667/4885SLC6A3 191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.